Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01966952
Other study ID # 20130444-01H
Secondary ID
Status Terminated
Phase N/A
First received October 16, 2013
Last updated February 8, 2015
Start date September 2013
Est. completion date February 2015

Study information

Verified date February 2015
Source Ottawa Hospital Research Institute
Contact n/a
Is FDA regulated No
Health authority Canada: Ethics Review Committee
Study type Observational

Clinical Trial Summary

Renal sympathetic radioablation disrupts the nerves by high radiofrequency signal which creates localized heat, eliminates the signal and decrease blood pressure.

The main purpose of this study is to evaluate blood pressure 12 months after radioablation, and to evaluate the short and long-term effects of the renal radioablation on the extent of changes in urine catecholamines level, vascular stiffness, and sympathetic nerve activity as linked with the changes in blood pressure. The study will also evaluate the effect radioablation has on the renal arteries as well as develop teaching sessions for family physicians and other specialists to educate them on this new treatment.


Description:

The purpose of this study is to evaluate the efficacy, safety and selected mechanisms of renal sympathetic radioablation. The primary outcome of this study is change in BP 12 months post treatment as assessed from daytime average of systolic BP from 24-hr ABPM.

In this innovation program, we propose to evaluate the following aspects of renal sympathetic radioablation RSRA in Patients with Resistant HTN:

1. Efficacy:

Assessment of BP lowering effect in patients with true resistant HTN. In contrast to studies done so far, we will evaluate the true BP lowering effect of RSRA by performance of 24-hr ABPM prior to and at defined time points post procedure. We will screen out pseudohypertension using direct observed therapy. We will employ a rigorous protocol to include only patients with truly resistant HTN. Namely, we will screen for major forms of secondary HTN such as renal artery stenosis, pheochromocytoma, primary hyperaldosteronism, and Cushing's syndrome and exclude these patients from radioablation. We will also address the issue of white coat phenomena as a cause of false diagnosis of resistant HTN by 24-hr ABPM. This innovative approach will ensure a proper evaluation of the BP lowering potential of this method, as patients with secondary forms of HTN may not respond to RSRA. In contrast, those with white coat effect may show gradual improvement in BP control over time unrelated to RSRA.

2. Safety: Imaging of the renal arteries. Our patients will undergo CT angiogram imaging of their renal arteries prior to procedure and at defined time points afterwards. In studies reported so far, imaging of the renal arteries was not standardized. In animals (swines) subjected to RSRA using the same catheter, renal arteries showed fibrosis of 10-25% of the total media and underlying adventitia, with mild disruption of the external elastic lamina. Furthermore, a case report has been published documenting renal artery stenosis within 3 months post RSRA.

3. Education on diagnosis and treatment of resistant HTN. As resistant HTN is frequently misdiagnosed and consequently poorly treated, we will develop teaching sessions for family physicians, general internists, and subspecialists from this LHIN region to make them aware of issues related to diagnosis of true resistant HTN and to educate them on this new option of treatment.

4. Mechanism:

Effects of RSRA on Central Sympathetic Outflow, PWV, and aldosterone will be assessed pre and post RSRA and correlated to (changes in) BP prior to and at defined time points post RSRA.

Clinical relevance:

This is a new method for treatment of patients with resistant HTN. As our team has successfully treated two patients with resistant HTN in June 2012 (as the second team and centre in Canada), TOH/UOHI with experts in Clinical HTN, Nephrology, Interventional Cardiology and Interventional Radiology are uniquely positioned to establish and critically evaluate the suitability of this method for patients from our LHIN region. Pilot data on Pulse Wave Velocity, MSNA and aldosterone by RSRA will shed light on mechanisms involved in BP lowering by RSRA and will be used for the development of grant applications to Canadian peer review funding agencies.


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date February 2015
Est. primary completion date February 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adult patients (>18 years)

- resistant HTN defined as daytime BP readings above 140/90 mmHg (as assessed from 24-hr ABPM))

- on 4 or more BP lowering drugs

Exclusion Criteria:

- pregnant patients

- Secondary forms of hypertension

- patients with following conditions: eGFR <45 ml/min/1.75 m2,

- active infection,

- known coagulopathies,

- acute coronary syndrome and/or within 6 months post acute coronary event,

- clinically significant arrhythmias,

- within 6 months post stroke/TIA, severe liver disease;

- psychiatric disorders and/or otherwise unable to sign consent.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Canada The Hypetension Unit of The Ottawa Hospital Ottawa Ontario

Sponsors (2)

Lead Sponsor Collaborator
Ottawa Hospital Research Institute The Ottawa Hospital Academic Medical Association

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Education Finally, formal evaluation of our teaching lectures on Diagnosis and Management of Resistant HTN will be part of outlined CMEs. 24months No
Primary Blood pressure change post RSRA treatment Blood pressure(BP)will be assessed post Renal Radiosympathetic radioablation RSRA)by 24-hr Ambulatory blood pressure monitor (ABPM) using the daytime average of systolic BP 12 months Yes
Secondary efficacy changes in daytime average systolic BP by 24-hr ABPM at 1,3, 6,& 12 months post RSRA
- changes in urinary catecholamines, aldosterone, Pulse wave velocity(PWV), and Muscle Sympathetic Nerve activity (MSNA) at defined time points post treatment.
1-3-6-&12 months Yes
Secondary Safety Secondary safety outcomes will also include frequency of complications including development of renal artery stenosis post procedure, determined by CT angiogram. 12 months Yes
See also
  Status Clinical Trial Phase
Withdrawn NCT01939392 - Rapid Renal Sympathetic Denervation for Resistant Hypertension II Phase 2/Phase 3
Completed NCT01699529 - Multi-electrode Radiofrequency Renal Denervation System Feasibility Study N/A
Completed NCT01418261 - SYMPLICITY HTN-3 Renal Denervation in Patients With Uncontrolled Hypertension N/A
Completed NCT01635998 - Adjunctive Renal Denervation in the Treatment of Atrial Fibrillation N/A
Completed NCT02674464 - Reducing Inequities in Care of Hypertension, Lifestyle Improvement for Everyone (RICH LIFE Project) N/A
Completed NCT04809519 - Integrative Nursing Based Multimodal Interventions for Uncontrolled Hypertensives N/A
Completed NCT01996033 - EnligHTN German Observational Study of Renal Denervation for Uncontrolled Hypertension
Terminated NCT01628198 - Impact of Renal SympAthetic DenerVation on Chronic HypErtension N/A
Recruiting NCT03221114 - Positive Psychology Intervention for Spanish-speaking Hispanic/Latino Adults at Risk for Cardiovascular Disease N/A
Completed NCT04248530 - DENEX Renal Denervation in Patients With Uncontrolled Hypertension: Safety Study N/A
Recruiting NCT06034743 - A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension Phase 3
Completed NCT02006758 - Observational Study of the EnligHTN Renal Denervation System in Europe
Active, not recruiting NCT03209154 - An Interventional Multidisciplinary Approach to Individualize Blood Pressure Treatment N/A
Withdrawn NCT05352425 - Effect of the MobiusHD® in Renal Hemodialysis Subjects With Uncontrolled Hypertension N/A
Completed NCT05395403 - Use of Automated Office Blood Pressure Monitoring N/A
Recruiting NCT05732727 - Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease Phase 3
Completed NCT02418091 - Integrated Population Program for Diabetic Kidney Disease N/A
Not yet recruiting NCT05234788 - Renal Artery DenervatIon Using Radial accesS in Uncontrolled HyperTensioN N/A
Completed NCT00888433 - Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2) N/A
Recruiting NCT05460169 - Renal Denervation in ADPKD- RDN-ADPKD Study N/A